FLT3-Mutated AML / Leukemia 07/28/2026

Ep. 4: FLT3-Mutated AML: Targeted Therapy From Diagnosis Through Long-Term Management

Healthy woman smiling with dark hair and white coat, healthcare professional, medical environment, oncology specialist, cancer treatment, OncUpdates, medical research, patient care, healthcare provider, medical expert. Uma Borate, MBBS A professional male doctor in a suit, smiling confidently against a neutral background, representing oncology and cancer treatment expertise. Naval Daver, MD Professional portrait of a smiling man in a dark suit and blue tie, with a neutral gray background, suitable for medical or corporate profiles. Nicholas Short, MD Smiling man with beard wearing a white shirt, professional headshot, suitable for oncology or cancer research content, emphasizing healthcare and medical expertise. Rahul Gosain, MD, MBA Oncologist smiling in white coat, highlighting cancer research and treatment expertise, with a bow tie, in a bright medical setting. Rohit Gosain, MD

Key Points

  • Patient selection, comorbidities, and treatment goals should guide decisions between combination regimens and FLT3 inhibitor monotherapy.
  • Toxicity management, including monitoring for QTc prolongation, cytopenias, differentiation syndrome, and liver function abnormalities, is critical to maximize treatment benefit.
  • Close collaboration between academic leukemia centers and community oncologists supports safe delivery of FLT3-directed therapy and long-term patient management.

During a recent Clinical Insights discussion, Rohit Gosain, MD, of Roswell Park Comprehensive Cancer Center, and Rahul Gosain, MD, MBA, of Wilmot Cancer Institute, were joined by Uma Borate, MBBS, of The Ohio State University, and Naval Daver, MD, and Nicholas Short, MD, both of The University of Texas MD Anderson Cancer Center, to review practical considerations for incorporating FLT3 inhibitors into the management of acute myeloid leukemia (AML). Beyond discussing efficacy, the panel’s final segment focused on patient selection, toxicity management, and strategies for coordinating care between academic leukemia centers and community oncology practices. 

Dr. Borate emphasized that treatment selection should be individualized according to patient fitness, comorbidities, and treatment goals. For older or medically frail patients who are unlikely to tolerate intensive combination therapy, single-agent FLT3 inhibitors may provide a more appropriate balance between disease control and quality of life. The panel also highlighted practical considerations unique to quizartinib, including the FDA Risk Evaluation and Mitigation Strategy (REMS) program, which is designed to educate clinicians about QTc prolongation and appropriate cardiac monitoring.

The experts reviewed several important adverse events associated with FLT3 inhibitors and strategies to minimize treatment-related toxicity. Dr. Borate noted that prolonged cytopenias remain the most common challenge with combination regimens, but growth factor support can be safely incorporated after marrow remission is confirmed to shorten neutropenia without adversely affecting relapse risk or survival. Dr. Short outlined the differing toxicity profiles among currently available FLT3 inhibitors, noting that midostaurin is more commonly associated with gastrointestinal adverse events and constitutional symptoms, whereas quizartinib requires careful electrocardiographic monitoring because of QTc prolongation risk. 

Although differentiation syndrome is less common with gilteritinib than with other targeted agents such as IDH or menin inhibitors, the panel noted that clinicians should remain vigilant for this potentially serious complication while also monitoring liver function tests, creatine kinase \, and electrolytes throughout therapy.

The discussion concluded by emphasizing the importance of coordinated care between academic and community oncology practices. Dr. Daver explained that patients often initiate therapy at specialized leukemia centers, where intensive first-cycle monitoring allows clinicians to optimize dosing, provide supportive care, and assess treatment response. Once remission is achieved and therapy is stabilized, many patients transition back to their local oncology teams for ongoing treatment, with regular communication maintained between institutions. The panel agreed that this collaborative model enables patients to receive highly specialized care close to home, ensuring appropriate monitoring of FLT3 inhibitor therapy and facilitating timely adjustments as treatment needs evolve.